What is ALLR's current stock price?

ALLR (Allarity Therapeutics, Inc.) is currently trading at $1.77 with a market cap of $28.2M.

What sector is Allarity Therapeutics, Inc. in?

Allarity Therapeutics, Inc. (ALLR) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

ALLR Allarity Therapeutics, Inc.

Healthcare

$1.77+6.63%ClosedMarket Cap: $28.2M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

4.08

P/S

81.63

EV/EBITDA

-2.69

DCF Value

$1.33

FCF Yield

-59.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

107.5%

Operating Margin

-3552.8%

Net Margin

-3260.6%

ROE

-109.9%

ROA

-32.2%

ROIC

-43.1%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$25.0K	$-2.8M	$—
Q4 null	$320.0K	$-3.4M	$—
FY null	$320.0K	$-11.2M	$—
Q3 null	$0.00	$-2.8M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Ascendiant CapitalBuy

2026-04-10

Ascendiant CapitalBuy

2025-12-09

Ascendiant CapitalBuy

2025-09-26

Trading Activity

Insider Trades

View All

Jensen Thomasofficer: CEO

SellThu May 14

Hoeiland Jesperdirector

SellMon May 11

Hoeiland Jesperdirector:

SellMon May 11

McLaughlin Gerald W.director

SellThu May 07

Graff Jeremy R.officer: See Remarks

SellThu Apr 30

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.38

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

Peers